Cumulative Anthracycline Dose Calculator
Cumulative Anthracycline Dose Calculator
Total a patient’s anthracycline exposure as a doxorubicin-equivalent dose in mg/m², by three published factor sets at once, because they disagree: mitoxantrone’s conversion factor has been published as 4 and as 10.5 by reputable bodies, and this page prints both rather than choosing.
Doxorubicin-equivalent cumulative dose
5 agents, 3 published factor setsDoxorubicin 150, daunorubicin 180, mitoxantrone 30 mg/m2 cumulative; no epirubicin or idarubicin
Three published factor sets, and where they disagree
Three published sets are computed: current (BC Cancer, citing COG Long-Term Follow-Up Guidelines v6.0), cardiomyopathy-derived (Feijen 2019, IGHG 2025) and older haematological equivalence. Every factor and its source is in the first table below.
- why the factors disagree
- most published formulas were built on HAEMATOLOGICAL toxicity equivalence, and cardiac toxicity does not follow it. The survivor-cohort analysis that derived cardiac ratios directly found the haematological 4-to-1 mitoxantrone figure “appeared to significantly underestimate” long-term risk
- mitoxantrone, 4 to 10.5
- a 2.6-fold disagreement on one drug, given at low absolute doses so the factor does most of the work. BC Cancer annotates its revision, “increased from 4 to 10”; the cardiomyopathy-derived ratio is 10.5, which the IGHG panel called “reasonable to use”
- epirubicin and idarubicin, where evidence runs out
- the IGHG panel recommended ratios only for daunorubicin and mitoxantrone, declining epirubicin and idarubicin “because of insufficient quality evidence”. The 0.67, 0.8 and 5 here are figures in use, not figures with cardiac outcome data behind them
- pegylated liposomal doxorubicin, no factor at all
- BC Cancer states plainly that there is “no conversion factor to calculate doxorubicin equivalent doses” for it, and sets no lifetime limit, so it is not an input here. Inventing a factor to make the conversion look possible is the error that absence is there to prevent
Worked example
Doxorubicin 150, daunorubicin 180, mitoxantrone 30 mg/m2 cumulative; no epirubicin or idarubicin
Current set: 150 + 0.5 × 180 + 10 × 30 = 150 + 90 + 300 = 540 mg/m² equivalent
Cardiomyopathy-derived set: 150 + 0.6 × 180 + 10.5 × 30 = 150 + 108 + 315 = 573
Older haematological set: 150 + 0.83 × 180 + 4 × 30 = 150 + 149.4 + 120 = 419
Highest ÷ lowest = 573 ÷ 419.4 = 1.37-fold, a spread of 154 mg/m² on one unchanged exposure, and every one of the three is correctly computed from a published factor set
Almost all of the spread is the mitoxantrone: take it out and the three become 240, 258 and 299, a 1.25-fold spread driven by the daunorubicin factor alone
Published doxorubicin-equivalence factors, by source, and how far apart they are
| Agent | Current guidance | Cardiomyopathy-derived | Older haematological | Spread |
|---|---|---|---|---|
| Doxorubicin | 1 | 1 | 1 | None — the reference |
| Daunorubicin | 0.5 | 0.6 | 0.83 | 1.66-fold, up to 2-fold against formulas using 1 |
| Epirubicin | 0.67 | 0.8 | 0.67 | 1.19-fold; IGHG declined to recommend any ratio |
| Idarubicin | 5 | 5 (carried over) | 5 | No disagreement: no cardiac ratio exists |
| Mitoxantrone | 10 | 10.5 | 4 | 2.6-fold |
| Pegylated liposomal doxorubicin | No factor published | No factor published | No factor published | Not convertible — not an input here |
Published cumulative-dose figures, with what each is and whose cohort it came from
| Agent | Published figure | What it is |
|---|---|---|
| Doxorubicin | 550 mg/m² three-weekly; 700 mg/m² weekly | BC Cancer’s suggested lifetime limit, not a safety guarantee |
| Doxorubicin | 5% at 400, 26% at 550, 48% at 700 mg/m² | Estimated cumulative probability of congestive heart failure in 630 patients on the doxorubicin-plus-placebo arms of three phase III trials (two breast, one small cell lung), 32 with heart failure |
| Doxorubicin | 3% at 400, 7% at 550, 18% at 700 mg/m² | The earlier Von Hoff estimates the same paper compared itself against, and found too low |
| Epirubicin | 720 to 1000 mg/m², risk rising more steeply above 900 | BC Cancer’s suggested lifetime limit |
| Daunorubicin | 900 mg/m², or 25 mg/kg | BC Cancer’s suggested lifetime limit |
| Mitoxantrone | 160 mg/m² | BC Cancer’s suggested lifetime limit |
| Idarubicin | No lifetime limit suggested | BC Cancer |
| Pegylated liposomal doxorubicin | No lifetime limit suggested | BC Cancer |
A conversion whose factors are contested, and why
Anthracycline cardiotoxicity is cumulative and largely irreversible, so the question that matters in survivorship care and in deciding whether more can be given is not which drug a patient had but how much total exposure they carry. Putting several agents on one scale needs conversion factors, and the factors in circulation disagree by a factor of 2.6 on mitoxantrone and 2 on daunorubicin.
The reason is specific. Almost all the older formulas were built on haematological toxicity equivalence, because that is what the short registration trials could measure, and cardiac toxicity turns out not to follow it. When a pooled analysis of 28,423 survivors of childhood cancer — from the Childhood Cancer Survivor Study, the Dutch LATER study and the St Jude Lifetime cohort, with 399 cardiomyopathy cases over a median twenty years — derived ratios from cardiomyopathy directly, the answers moved both ways: daunorubicin to 0.6 rather than the 1 most formulas assumed, and mitoxantrone to 10.5 rather than 4, the authors writing that the haematological figure “appeared to significantly underestimate” the long-term risk. That mitoxantrone is an anthraquinone rather than an anthracycline is part of why borrowing a haematological ratio went wrong. BC Cancer’s current table now uses 0.5 and 10 and annotates both as revisions of 0.83 and 4, while the 2025 harmonisation panel endorsed 0.6 and 10.5 as “reasonable to use” and declined any ratio for epirubicin or idarubicin “because of insufficient quality evidence”. The idarubicin 5 is identical across all three sets not because anyone agrees but because nobody has revised it, and pegylated liposomal doxorubicin has no published factor at all.
What this page will not do is give a safe limit. The published cumulative figures are suggested limits and cohort probabilities, and the two doxorubicin rows in the second table show why those differ: one analysis of 630 patients put the probability of congestive heart failure at 550 mg/m² at 26% where the earlier estimate had been 7%, concluding that heart failure occurs “with greater frequency and at a lower cumulative dose than previously reported”. Whether a patient can have more anthracycline is a cardio-oncology judgement made with imaging and a cardiac history in front of it. A figure from a cohort is not this patient’s outcome and a response category is not a diagnosis: a stratum in which 42 per cent were alive at fifteen years tells you about that stratum, not which 42 per cent. This page computes a published quantity and states the criteria behind it. It renders no dose, no prescription and no treatment decision — that is the treating team’s. Every coefficient, conversion factor and threshold here is attributed to the source it was read in and, where it is a prognostic figure, to its derivation cohort; where the treating protocol differs, the protocol takes precedence.
Frequently asked questions
How do I convert epirubicin or mitoxantrone to a doxorubicin-equivalent dose?
Multiply each agent’s cumulative mg/m² by its factor and add them up. Current guidance gives daunorubicin 0.5, epirubicin 0.67, idarubicin 5 and mitoxantrone 10, with doxorubicin as 1; the cardiomyopathy-derived ratios give 0.6, 0.8 and 10.5.
Why do published anthracycline conversion factors disagree?
Because most were derived from haematological toxicity equivalence and cardiac toxicity does not follow it. A pooled analysis of 28,423 childhood cancer survivors derived ratios from cardiomyopathy directly and found daunorubicin less cardiotoxic than assumed and mitoxantrone far more so: the haematological 4-to-1 figure, its authors wrote, appeared to significantly underestimate the long-term risk.
What is the safe cumulative anthracycline dose?
There is no dose at which cardiotoxicity risk is zero, and this page gives no limit. BC Cancer suggests 550 mg/m² for doxorubicin three-weekly, and an analysis of 630 patients estimated a 26% cumulative probability of congestive heart failure at that dose against 5% at 400 mg/m² — cohort probabilities, modified by chest radiotherapy, age and cardiac comorbidity.
Is the idarubicin factor of 5 reliable?
It is the least well supported number here: a haematological-equivalence figure, with no cardiotoxicity study read for this page deriving an idarubicin ratio. The pooled survivor analysis had too few cases, and the 2025 harmonisation panel declined to recommend one. The three sets agree on 5 only because none has revised it.
Related calculators
References
- BC Cancer. Pharmacy FAQ: lifetime cumulative doses, Table 1. Vancouver: Provincial Health Services Authority.
- Feijen EAM, Leisenring WM, Stratton KL, et al. Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity. JAMA Oncol. 2019;5(6):864–71, as reported in The ASCO Post and by Fred Hutchinson Cancer Center.
- IGHG recommendations for anthracycline and anthraquinone cardiac dysfunction equivalence ratios after childhood cancer: JACC: CardioOncology expert panel. 2025, as summarised by the American College of Cardiology.
- Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–79.
- Childhood Cancer Survivor Study. Concept proposal 16-09: derivation of anthracycline equivalence to doxorubicin, Table 1. Memphis: St Jude Children’s Research Hospital.
Not medical advice. For healthcare professionals and education. Reference intervals vary by laboratory and assay — always use your own laboratory's. Never base a dose or a treatment decision on this page alone. Full disclaimer at calcengines.com/disclaimer/